Product Pipeline
BEXXAR® (tositumomab, iodine I 131 tositumomab) is an investigational radioimmunotherapy that combines the targeting ability of a monoclonal antibody and the therapeutic potential of radiation, with patient-specific dosing. We are seeking initial FDA approval of BEXXAR for treating follicular low-grade non-Hodgkin’s lymphoma (NHL). This patient population includes patients with transformed low-grade NHL and patients who have relapsed after, or are refractory to, chemotherapy. We are also simultaneously pursuing additional BEXXAR clinical trials.

Related News
06/27/2002 FDA grants Corixa's appeal for BEXXAR®
05/31/2002 Corixa files request for formal dispute resolution with FDA on BEXXAR®
05/15/2002 Corixa announces results of BEXXAR® discussions with the FDA
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.